

### Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
石田也寸志	血液・腫瘍性疾患 患児への告知とターミナルケア	大関武彦他	今日の小児治療 指針第15版	医学書院	東京	2011	418-419
石田也寸志 細谷亮太	悪性腫瘍（診断と 治療、ターミナル ケア）	小野次朗 西牧謙吾 榊原洋一	教育現場における「病弱・障害児 の生理病理心理」	ミネルヴァ 書房	京都	2011	86-102
石田也寸志	血液・腫瘍性疾患 患児への告知とターミナルケア	大関武彦、古 川漸他	今日の小児治療 指針 第15版	医学書院	東京	2011	418-419
石田也寸志	長期合併症と長期 フォローアップ	赤司浩一 上田孝典他	血液専門医テキスト	南江堂	東京	2011	461-464
石田也寸志	小児がん治療の進 歩と長期フォロー アップの必要性 ウイルス腫瘍 化学療法	石田也寸志 ・前田美穂編	よくわかる小児 がん経験者のた めに～よりよい 生活の質(QOL)を 求めて～	医薬ジャー ナル社	大阪	2011	12-14 50-53 79-81
石田也寸志	小児がん経験者の 長期フォローアッ プ	堀部敬三	小児がん診療ハ ンドブック	医薬ジャー ナル社	大阪	2011	46-56
前田美穂	長期フォローアッ プガイドライン概 説	監修 加藤俊 一、石田也寸 志、前田美穂 編	よくわかる小児 がん経験者のた めに	医薬ジャー ナル社	大阪	2011	15-19
前田美穂	急性リンパ性白血 病 疾患別のポイ ント	監修 加藤俊 一、石田也寸 志、前田美穂 編	よくわかる小児 がん経験者のた めに	医薬ジャー ナル社	大阪	2011	20-24
前田美穂	輸血 治療によ る注意点	監修 加藤俊 一、石田也寸 志、前田美穂 編	よくわかる小児 がん経験者のた めに	医薬ジャー ナル社	大阪	2011	78
前田美穂	循環器 臓器別・ 機能別のポイント	監修 加藤俊 一、石田也寸 志、前田美穂 編	よくわかる小児 がん経験者のた めに	医薬ジャー ナル社	大阪	2011	110-112
前田美穂	小児血液・腫瘍性 疾患のキャリアー オーバーと長期フォ ローアップ	大関武彦他	今日の小児治療 指針 第15版	医学書院	東京	2011	552-553
前田美穂	晩期合併症対策	堀部敬三編	小児がん診療ハ ンドブック	医薬ジャー ナル社	大阪	2011	314-322
堀浩樹	インフォームドコ ンセント・アセン ト	堀部敬三	小児がん診療ハ ンドブック	医薬ジャー ナル社	大阪	2011	26-31
堀浩樹	急性骨髄性白血病	加藤俊一	よくわかる- 小 児がん経験者の ために	医薬ジャー ナル社	大阪	2011	25-28

堀浩樹	横紋筋肉腫	加藤俊一	よくわかる－小児がん経験者のために	医薬ジャーナル社	大阪	2011	54-57
堀浩樹	肝芽腫	加藤俊一	よくわかる－小児がん経験者のために	医薬ジャーナル社	大阪	2011	58-60
堀浩樹	運動器	加藤俊一	よくわかる－小児がん経験者のために	医薬ジャーナル社	大阪	2011	132-135
堀浩樹	予防接種	加藤俊一	よくわかる－小児がん経験者のために	医薬ジャーナル社	大阪	2011	143-145

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Kuroda T</u>	Cellular kinetics of neuroblastoma and the role of surgery	Pediatric surgery international	27(9)	913-917	2011
<u>Kuroda T</u> , Kumagi M, Nosaka S, Nakazawa A, Hoshino K, Takimoto T	Critical infantile hepatic hemangioma: results of a nationwide survey by the Japanese Infantile Hepatic Hemangioma Study Group	Journal of Pediatric Surgery	46(12)	2239-2243	2011
<u>Ishida Y</u> , et al	Physician Preferences and Knowledge Regarding the Care of Childhood Cancer Survivors in Japan: A Mailed Survey of the Japanese Society of Pediatric Oncology	Jap J Clin Oncology	28	878-883	2012
<u>Ishida Y</u> , et al	Factors Affecting Health Care Utilization for Children in Japan	Pediatrics	129	e113-e119	2012
Deshpande GA, Soejima K, <u>Ishida Y</u> et al	A global template for reforming residency without workhours restrictions: Decrease caseloads, increase education. Findings of the Japan Resident Workload Study Group	Medical Teacher		(In Press)	2012
Sato I, Higuchi A, Yanagisawa T, <u>Ishida Y</u> , et al	Factors influencing self- and parent-reporting health related quality of life in children with brain tumors	Quality of Life Research		DOI 10.1007/S11136-012-0137-3	2012
<u>Ishida Y</u> , et al	Social outcomes and quality of life (QOL) of childhood cancer survivors in Japan: A cross-sectional study on marriage, education, employment and health related QOL (SF-36)	Int J Hematol	93(5)	633-644	2011
<u>Ishida Y</u> , et al	Medical Visits of Childhood Cancer Survivors in Japan: A Cross-sectional survey	Pediatrics Int	53(3)	291-299	2011
WatanabeS, Azami Y, Ozawa M, <u>Ishida Y</u> . et al	Intellectual development after treatment in children with acute leukemia and brain tumor	Pediatrics Int	53	694-700	2011

Naoko Tsuji, Naoko Kakee, Yasushi Ishida et al:	Validation of the Japanese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module	Health and Quality of Life Outcomes	9	22-	2011
Ohde S, Hayashi A, Takahashi O, Yamakawa S, Nakamura M, Osawa A, Ishida Y et al	A 2-week prognostic prediction model for terminal cancer patients in a palliative care unit at a Japanese general hospital	Palliative medicine	25(2)	170-17	2011
T Asano, K Kogawa, A Morimoto, Y Ishida et al:	Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: A nationwide survey in Japan	Pediatr Blood Cancer		DOI 10.1002/pbc.23384	2011
Tokuda Y, Goto E, Ishida Y et al	The New Japanese Postgraduate Medical Education and Quality of Emergency Medical Care	J Emerg Med		1-8	2011
Hasegawa D, Manabe A, Ishida Y et al	The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study	Pediatr Blood Cancer	58(1)	23-30	2011
Asami K, Ishida Y, Sakamoto N	Job discrimination against childhood cancer survivors in Japan - a cross-sectional survey	Pediatr Int		(In Press)	2011
石田也寸志、細谷亮太	小児がん治療後のQOL－Erice宣言と言葉の重要性－	日本小児科学会雑誌	115	126-131	2011
石田也寸志、山口悦子、堀浩樹他	小児急性リンパ芽球性白血病患児・家族のQOLアンケート調査－第1報	日本小児科学会雑誌	115(5)	918-930	2011
石田也寸志、山口悦子、堀浩樹他	小児急性リンパ芽球性白血病患児・家族のQOLアンケート調査－第2報	日本小児科学会雑誌	15(5)	931-942	2011
石田也寸志、渡辺静、小澤美和、他	小児がん経験者の晩期合併症の予測は可能か－聖路加国際病院小児科の経験－	日本小児血液がん学会雑誌		(印刷中)	2012
石田也寸志、本田美里、坂本なほ子、他	小児がん経験者の横断的調査研究における自由記載欄の解析	日本小児科学会雑誌		(印刷中)	2012
石田也寸志	シクロスポリン、タクロリムスによるけいれん・意識障害	小児内科	43	615-617	2011
石田也寸志	成人した小児白血病経験者の移行期支援	Nursing Today	26	30-35	2011
石田也寸志	成人した小児がん経験者の課題	小児保健研究	70	182-186	2011
石田也寸志	何に気をつけて治療後の経過を診ていけばよいですか？	治療	93	1184-1186	2011
石田也寸志	小児がん経験者の長期フォローアップ-成人期の移行について	保健の科学	53	522-526	2011
石田也寸志	小児がん経験者の晩期合併症およびQuality of Life(QOL)に関する横断的研究	小児外科	43	1234-1237	2011
石田也寸志、細谷亮太	小児のインフォームド・コンセントやインフォームド・アセントは何歳からどのように得ればよいですか？	小児内科	43	29-31	2011

居石崇志、石田也寸志、 草川功、細谷亮太	「実地医家の小児科診療—ここ がポイント」腸重積	日本医事新 報	4538	44-47	2011
小田原紗羅、小野林太郎、 小澤美和、石田也寸志、 荻原正明、細谷亮太	「実地医家の小児科診療—ここ がポイント」熱性痙攣	日本医事新 報	4543	44-47	2011
森田有香、吉原宏樹、野 崎太希、石田也寸志 細谷亮太	「実地医家の小児科診療—ここ がポイント」小児虐待の画像所見	日本医事新 報	4547	44-47	2011
候聡志、米川聡子、稲井 郁子、石田也寸志、細谷 亮太	「実地医家の小児科診療—ここ がポイント」新しい予防接種	日本医事新 報	4551	44-47	2011
小野林太郎、石田也寸志、 細谷亮太	「実地医家の小児科診療—ここ がポイント」小児の敗血症—敗血 症は血液培養陽性ではない—	日本医事新 報	4556	44-47	2011
米川聡子、神谷尚宏、石 田也寸志、細谷亮太	「実地医家の小児科診療—ここ がポイント」小児の肥満—Let's Move	日本医事新 報	4560	44-47	2011
馬場徳朗、中川真智子、 石田也寸志、真部淳、細 谷亮太	「実地医家の小児科診療—ここ がポイント」新生児B群溶連菌感 染症	日本医事新 報	4564	44-47	2011
Taguchi T, Nagata K, Kinoshita Y, Ieiri S, Tajiri T, Teshiba R, Esumi G, Karashima Y, Hoka S, Masumoto K	The utility of muscle sparing axillar skin crease incision for pediatric thoracic surgery	<u>Pediatr</u> <u>Surg Int</u>	28(3)	239-244	2012
Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T, Tanaka M, Onishi H, Katano M	Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer	Cancer Sci	102(2)	373-381	2011
Souzaki R, Tajiri T, Teshiba R, Higashi M, Kinoshita Y, Tanaka S, Taguchi T.	The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma	Pediatr Surg Int	27(3)	231-236	2011
原純一、池田均、瀧本哲 也	日本小児がん学会小児がん全数 把握登録事業（2009年12月改訂） による2008年、2009年診断症例の 集計結果	小児がん	48	150-174	2011
Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H.	Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data	Cancer Sci.			2012 Feb 25. doi: 10.1111/ j.1349-7 006.2012 .02254.x
Ito Y, Nakayama T, Tsukuma H, Miyashiro I, Ioka A, Sugimoto T, Rachet B.	Role of age and tumour stage in the temporal pattern of 'cure' from stomach cancer: A population-based study in Osaka, Japan.	Cancer Epidemiol.	36	128-132	2012 Jan 31. [Epub ahead of print]
Nomura E, Ioka A, Tsukuma H.	Trends in the incidence of primary intracranial tumors in Osaka, Japan	Jpn J Clin Oncol.	41(2)	291-4	2011
Ito Y, Ioka A, Nakayama T, Tsukuma H, Nakamura T.	Comparison of trends in cancer incidence and mortality in osaka, Japan, using an age-period-cohort model	Asian Pac J Cancer Prev.	12	879-888	2011
前田美穂	小児がん 治療後、将来妊娠への 影響はありますか？	治療	93(4)	1187-1189	2011

前田美穂	ライフスパンから見た小児科診療. 腫瘍疾患- 晩期合併症 血液腫瘍性疾患.	小児内科	43 (9)	1481-1486	2011
工藤寿子	悪性腫瘍の患児と両親への精神的サポート-医師の立場から	小児外科	44	139-142	2012
堂下雅也、堀浩樹、世古口さやか、豊田秀実、岩本彰太郎、駒田美弘	小児がん・難治性血液疾患患児の入院中の食事状況	小児がん	48 (2)	119-124	2011
Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T	Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses	Int J Oncol	38 (4)	911-019	2011
Iwamoto S, Deguchi T, Ohta H, Kiyokawa N, Tsurusawa M, Yamada T, Takase K, Fujimoto J, Hanada R, Hori H, Horibe K, Komada Y	Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group	Int J Hematol	94 (2)	185-92	2011
Shuhei Karakawa, Satoshi Okada, Miyuki Tsumura, Yoko Mizoguchi, Norioki Ohno, Shin' ichiro Yasunaga, Motoaki Ohtsubo, Tomoki Kawai, Ryuta Nishikomori, Takemasa Sakaguchi, Yoshihiro Takihara, Masao Kobayashi.	Decreased Expression in Nuclear Factor- $\kappa$ B Essential Modulator Due to a Novel Splice-Site Mutation Causes X-linked Ectodermal Dysplasia with Immunodeficiency	J Clin Immunol	31 (5)	762-772	2011
Yohko Kyo, Takeo Tanaka, Kunihiko Hayashi, Tomoko Iehara, Michio Kaneko, Hajime Hosoi, Tohru Sugimoto, Minoru Hamasaki, Masao Kobayashi, Tadashi Sawada	Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IV	Cancer Lett.	306 (1)	27-33	2011
新井紀子、加藤寿宏、足立壮一、松島佳苗	造血細胞移植後患児の認知機能検査とQOLの調査	作業療法	31 (3)	(印刷中)	2012



#### IV. 研究成果の刊行物・別刷

# Cellular kinetics of neuroblastoma and the role of surgery

Tatsuo Kuroda

Accepted: 6 July 2011 / Published online: 19 July 2011  
© Springer-Verlag 2011

**Abstract** Neuroblastoma is known for its peculiar cellular kinetics, which has provoked some controversy regarding surgical treatment. Highly sensitive exploration systems using reverse transcription polymerase chain reaction (RT-PCR) methods have been developed to detect neuroblastoma cells. In our series of 49 patients with advanced neuroblastoma, circulating tumor cells (CTC) were detected by this system in 55.6% of the stage 4 patients who were examined, suggesting that the primary lesion may release tumor cells into the peripheral blood. The Kaplan–Meier survival rate was significantly lower among the patients with CTC or chemotherapy-insensitive bone marrow micrometastasis, compared with those without detectable micrometastasis (33.8 vs. 87.5%,  $P < 0.05$ ). In contrast, a stage 3 patient with MYCN amplification exhibited drastic local relapse without systemic dissemination of the disease. Two patients were positive for CTC without an identifiable primary site. These observations indicate that the local growth of the primary tumor and tumor cell dissemination may be regulated by different molecular mechanisms in neuroblastomas. MYCN amplification seemed to be more closely associated with localized tumor growth but was minimally correlated with CTC positivity. High-risk neuroblastoma may include two separate subgroups characterized by different cellular kinetics: a local risk cohort and a systemic risk cohort. Surgical strategies for neuroblastoma should be determined with taking this cellular kinetics into consideration.

**Keywords** Neuroblastoma · Cellular kinetics · Circulating tumor cell · Micrometastasis · Surgery

## Introduction

Surgical treatment for neuroblastoma has been controversial. Without a doubt, surgery is a major therapeutic tool for macroscopic lesions. However, not only macroscopic tumors, but also the invisible spreading of tumor cells must be considered in cancer treatment strategies. This consideration is especially important for neuroblastomas, because neuroblastoma has peculiar cellular kinetics. Methods for detecting extremely small amounts of neuroblastoma cells have been developed and applied clinically to some extent, providing some suggestions regarding the cellular kinetics of this disease. On the other hand, the prognostic significance of micrometastasis has not been established for neuroblastomas. In the current review, these problems are described and our own experiences are presented.

## Cellular kinetics of neuroblastoma

The unique clinical features are well known in neuroblastoma. Classically, a proportion of infantile patients who show massive metastases to the liver, bone marrow, and skin despite the presence of a small primary tumor has been described and is known as “stage IVS” [1]. The spontaneous regression of both the primary tumor and metastases are commonly observed in this unique population. Subsequently, the role of nerve growth factor and its receptor, trk A, has been clarified in the mechanism of the apoptosis of infantile neuroblastoma [2]. Previously, we reported a series of older cases of neuroblastoma that had no

T. Kuroda (✉)  
Department of Pediatric Surgery, Keio University,  
School of Medicine, 35 Shinanomachi,  
Shinjuku-ku, Tokyo 160-8582, Japan  
e-mail: kuroda-t@z8.keio.jp




radiologically identifiable primary tumor despite massive systemic metastases [3]. These clinical observations suggest that the local growth of the primary tumor and the systemic spreading of the tumor cells may be controlled by separate molecular mechanisms in neuroblastomas. The respective factors affecting the growth of primary and metastatic neuroblastomas have not been fully identified at present. How the primary tumor and the metastatic tumors grow independently also remains unknown. From the clinical point of view, studies on the mechanism of this peculiar form of cellular kinetics for neuroblastoma are definitely important in relation to the control of tumor growth and spreading.

### Detection of neuroblastoma cells

To trace the cellular kinetics, the development of a highly sensitive method is required to detect neuroblastoma cells. Several methods have been developed to detect tumor cells with a very high sensitivity for some cancers. Immunocytochemical methods can detect tumor cells with a sensitivity of 1/10,000, and clinical applications of these methods have often been reported for patients with leukemia [4–6] as well as neuroblastoma [7, 8]. In the 1980s, molecular biological techniques became widespread. Using reverse transcriptase polymerase chain reaction (RT-PCR) method, a selected sequence of tumor-specific genomic mRNA can be amplified and visualized, enabling the detection of tumor cells amidst more than  $10^6$  mononuclear cells. More recently, nested PCR or a second PCR to increase the sensitivity even further as well as quantitative PCR have become more common. Several researchers have reported that the quantitative evaluation of the minimal residual disease might provide a higher prognostic value in the selected cancers including neuroblastoma [9–11]. These techniques enable the detection of micrometastases that are totally undetectable using conventional radiological imaging tools and microscopic exploration. Several trials, including our own, have explored the presence of extremely low levels of neuroblastoma cells in the peripheral blood and bone marrow [9, 12–17] (Fig. 1).

On the other hand, the most suitable molecular marker for specific cancers has not been established for many malignancies. Some markers provide a higher sensitivity, but a lower specificity. Tyrosine hydroxylase, PGP9.5 [18, 19], and, more recently, GD2 synthetase [20], GAGE [21], and cyclin D1 [22] have been named as specific markers of neuroblastoma cells. More than 95% of neuroblastomas exhibit a catecholamine biosynthesis pathway in their tumor cells [23]. Tyrosine hydroxylase is the first and rate-limiting enzyme of this pathway, and specifically expressed in most neuroblastoma cells. Thus, tyrosine hydroxylase



**Fig. 1** Exploration of bone marrow micrometastasis of neuroblastoma using a single PCR method. *Lanes 1 and 2* IMR-32 cell line as the positive control. *Lanes 3–6* bone marrow samples harvested from four neuroblastoma patients. *Case 3 (Lane 5)* showed positive signal for neuroblastoma at 256 bp, as observed in the positive control

mRNA is most commonly used as a molecular marker for neuroblastoma cells. Practically, several types of tyrosine hydroxylase mRNA synthesized using alternate splicing in exons 1 and 2 have been identified [24–26]. Therefore, the primers are usually designed to encode a common sequence region so as to detect all types of tyrosine hydroxylase mRNA [27].

The appropriate sensitivity of the PCR exploration is another problem that remains unsolved. The expression of genomic mRNA by contaminated leucocytes in a very small amount has been described as ectopic RNA. Two-step PCR methods possibly detect these non-specifically expressed mRNA [28]. Future clinical studies may be directed to standardize the methodology employed to detect micrometastatic neuroblastoma. Therefore, at present, all the staging and risk grouping systems are based on light microscopic observation.

### Circulating tumor cells

In our own series of 49 patients with advanced neuroblastoma, who were treated between 1991 and 2007, circulating tumor cells (CTC) in the peripheral blood were detected in 55.6% of the stage 4 patients using our previously described single RT-PCR method [29]. The above two patients who exhibited massive metastases without an identifiable primary site also presented CTC positivity regardless of MYCN copy numbers. All the deaths in this cohort of patients with CTC were related to the systemic dissemination of the disease. CTC positivity was not detected in any of the stage 3 patients at this sensitivity level. The detection of CTC was not associated with MYCN amplification. The positive rate was 44.4% among the patients with amplified MYCN and 46.2% among the

patients with a single copy of MYCN [29]. Clinically, 75% of the patients who developed relapse with disseminated metastasis, had a single copy of the MYCN oncogene, whereas all the patients who developed local tumor relapse, showed amplification of MYCN (although the number of patients in this group was not large) [3].

These clinical observations suggest the following hypothetical model explaining the cellular kinetics in neuroblastomas. Tumor cells may grow at the primary site and, simultaneously, translocate into the peripheral blood as CTC to form distant metastases, which may be regulated by molecular mechanisms other than those controlling the local tumor growth (Fig. 2). Potentially, these primary and metastatic lesions may both become sources of CTC. Although the amplification of the MYCN oncogene is closely associated with localized tumor growth, it may be minimally correlated with the systemic dissemination of the disease.

In addition, these observations highlighted the existence of two clinical subgroups exhibiting different cellular kinetics in advanced neuroblastoma patients: a systemic risk cohort with CTC positivity, and a local risk cohort characterized by MYCN amplification but without micrometastasis. These two cohorts may correspond to the two categories in the INRG high-risk group [30].

### Prognostic significance of micrometastasis


Although the prognostic significance of micrometastasis or CTC in the peripheral blood is better established for some of the hematological cancers, it remains controversial in neuroblastoma [9, 12–15]. We reported previously that the Kaplan–Meier survival rate was 42.0% in patients with CTC positivity in our series, and was definitely lower than that of 90.0% of the patients with no detectable CTC [29]. In our series, micrometastasis to the bone marrow was detected in 72.2% of the stage 4 patients who were examined. The positive rate was 85.7% in the patients with CTC positivity and 50% in the patients without detectable

tumor cells in the peripheral blood. The temporary appearance of bone marrow micrometastasis did not affect the clinical outcome in our series. However, the persistent bone marrow micrometastasis after chemotherapy, which was detected in half of the patients, seemed to be associated with a poor prognosis. Combining these results, the Kaplan–Meier analysis showed a statistically significant difference in the survival rate between patients with CTC positivity and/or persistent bone marrow micrometastasis and those without detectable micrometastasis (33.8 vs. 87.5%;  $P < 0.05$ ). Thus, our observations support a hypothesis that the presence of micrometastasis can be regarded as an independent clinical risk factor other than MYCN amplification, and has strong clinical implication on the determination of treatment strategy in advanced neuroblastoma. Similar observation regarding the bone marrow micrometastasis was also reported from Japan [31]. In addition, since these micrometastases are often chemotherapy resistant, they may include a cancer stem cell-like population of neuroblastoma cells, such as side population cells or tumor-initiating cells. More recently, Hansford et al. [32] succeeded in identifying a highly tumorigenic cell population in the bone marrow of neuroblastoma patients. Future study may be directed to control the proliferation of these cell populations.

### Optimal local treatment

In recent concepts for neuroblastoma surgery, risk assessment has been emphasized in the design of surgical strategies. Different strategies should be applied according to the risk assessment. Image-defined risk factor (IDRF) is a recently proposed concept used to evaluate image diagnostic findings in a standard manner in relation to the risk groupings of neuroblastoma [33]. In infants with low or intermediate risks who exhibit IDRFs, surgical extirpation may be abandoned. The risk benefit balance of surgical treatment and presumably a benign tumor biology determine the surgical strategy. An analysis of molecular markers provides important information regarding the biological features of tumors, enabling surgical risks to be avoided.

Among the high-risk patients, aggressive surgery would benefit patients in the local risk cohort the most. In contrast, for those in the systemic risk cohort, the clinical impact of intensive surgical treatment remains unestablished [34]. Several studies, including ours, have demonstrated the clinical significance of intensive local treatment for neuroblastoma patients with stage 4 disease, whereas other studies have not [35–37]. We previously observed that no local relapse occurred after completing total resection of the primary tumor, systemic lymph node



**Fig. 2** Hypothetic model for cellular kinetics of neuroblastoma

dissection, and intraoperative radiation (IOR) [35]. Nevertheless, all the patients with macroscopic residual tumor died within 1 1/2 year after surgery because of systemic metastasis in this series. These observations suggest that surgical eradication may be essential for long-term survival in all patients with high-risk neuroblastomas. The primary tumor might still act as a source of neuroblastoma cells which are released into the peripheral blood, even after chemotherapy and IOR, possibly resulting in systemic relapse. Hypothetically, local control may also play an important role in controlling the systemic dissemination of the disease. If so, reducing the surgical intensity could be considered dangerous also in patients with metastasis. Further studies would be still required to determine if surgical intensity could be reduced even for the cases of the systemic risk cohort.

On the other hand, an interesting clinical trial is now in progress in Japan. This novel trial is characterized by non-stop chemotherapy until mega-therapy with stem cell transplantation, combined with delayed local therapy, including surgery, until the end of the treatment course [38]. The most beneficial aspect of this new protocol is the avoidance of delays in chemotherapy because of surgical complications.

#### Consideration of quality of life during the distant post-therapeutic period

Another aspect that should be considered when deciding on the surgical strategy is the securement of a satisfying post-therapeutic quality of life. A high incidence of morbidity has been associated with intensive local treatment [39, 40]. IOR can be used to control the primary site completely; however, the morbidity rate after intensive surgery with IOR was as high as 33.3% in our series. Renal vascular problems were seen in 15.2% of the patients, representing the most common complication after IOR [41]. Thus, modern surgical guidelines for advanced neuroblastoma recommend less harmful surgery and lymph node sampling instead of systemic dissection, and direct to avoid resection of surrounding organs.

#### Conclusions

In summary, both local and systemic risk must be considered when deciding on a surgical strategy. Some of the clinical observations presented above suggest that local control and systemic control therapies for neuroblastoma may interfere with each other. Therefore, a suitable balance between local and systemic therapy is extremely important for the treatment of neuroblastoma. The suitability of

surgical therapy for neuroblastoma should be discussed also based on the observations of the cellular kinetics. Molecular biological tools may help pediatric surgeons to make appropriate decisions by providing a more detailed risk assessment in relation to the cellular kinetics.

**Acknowledgments** The summary of the present review was presented at the 3rd World Congress of Pediatric Surgery at New Delhi, India, on October 2010.

#### References

1. Evans AE, Chatten J, D'Angio GJ et al (1980) A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. *Cancer* 45:833–839
2. Nakagawara A (2001) Trk receptor tyrosine kinases: a bridge between cancer and neuronal development. *Cancer Lett* 169:107–114
3. Kuroda T, Honna T, Morikawa N et al (2005) Tumor cell dynamics and metastasis in advanced neuroblastoma. *Pediatr Surg Int* 21:859–863
4. Coustan-Smith E et al (1993) N-CAM(CD56) expression by CD34+ malignant myeloblasts has implication for minimal residual disease detection in acute myeloid leukemia. *Leukemia* 7:853
5. Dworzak MN et al (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. *Blood* 99:1952
6. McKenna RW et al (2001) Immunophenotypic analysis of hematogenes (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. *Blood* 98:2498
7. Moss TJ, Reynolds CP, Sather HN et al (1991) Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. *N Engl J Med* 324:219–226
8. Cheung IY, Barber D, Cheung NK (1998) Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. *Clin Cancer Res* 4:2801–2805
9. Cheung IY, Cheung NK (2001) Quantification of marrow disease in neuroblastoma by real-time reverse transcription-PCR. *Clin Cancer Res* 7:1698–1705
10. Pession A, Libri V, Sartini R et al (2003) Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma. *Oncol Rep* 10:357–362
11. Viprey VF, Corrias MV, Kagedal B et al (2007) Standardization of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. *Eur J Cancer* 43:341–350
12. Mattano LA Jr, Moss TJ, Emerson SG (1992) Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. *Cancer Res* 52:4701–4705
13. Helfrich W, ten Poele R, Meersma GJ et al (1997) A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. *Br J Cancer* 76:29–35
14. Burchill SA, Bradbury FM, Smith B et al (1994) Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. *Int J Cancer* 57:671–675
15. Lambooy LH, Gidding CE, van den Heuvel LP et al (2003) Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. *Clin Cancer Res* 9:812–819

16. Kuroda T, Saeki M, Mizutani S et al (1997) Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. *J Pediatr Surg* 32:69–72
17. Miyajima Y, Kato K, Numata S et al (1995) Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. *Cancer* 75:2757–2761
18. Wang Y, Einhorn P, Triche TJ et al (2000) Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. *Clin Cancer Res* 6:551–558
19. Gilbert J, Norris MD, Marshall GM et al (1997) Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma. *Br J Cancer* 75:1779–1781
20. Cheung IY, Lo Piccolo MS, Kushner BH et al (2003) Quantification of GD2 synthetase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. *J Clin Oncol* 21:1087–1093
21. Olta S, Martinez F, Orellana C et al (2004) Minimal residual disease in neuroblastoma: to GAGE or not to GAGE. *Oncol Res* 14:291–295
22. Cheung IY, Feng Y, Vickers A et al (2007) Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. *J Mol Diagn* 9:237–241
23. Schweisguth O (1979) *Tumeurs dela crete neurale*. In: Scweisguth O(ed) *Tumeurs solides del'enfant*, Flammarion, Paris, pp 165
24. Kobayashi K, Kaneda N, Ichinose H et al (1988) Structure of the human tyrosine hydroxylase gene: alternative splicing from a single gene accounts for generation of four mRNA types. *J Biochem* 103:907–912
25. O'Malley KL, Anhalt MJ, Martin BM et al (1987) Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5'- alternative splice sites responsible for multiple mRNAs. *Biochemistry* 26:2910–2914
26. Grima B, Lamouroux A, Boni C et al (1987) A single human gene encoding multiple tyrosine hydroxylase with different predicted functional characteristics. *Nature* 326:707–711
27. Naito H, Kuzumaki N, Uchino J et al (1991) Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction. *Eur J Cancer* 27:762–765
28. Rininsland F, Hahn A, Niemann-Seyde S et al (1992) Identification of a new DMD gene deletion by ectopic transcript analysis. *J Med Genet* 29:647–651
29. Kuroda T, Morikawa N, Matsuoka K et al (2008) Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. *J Pediatr Surg* 43:2182–2185
30. Castleberry RR, Pritchard J, Ambros P et al (1997) The International Neuroblastoma Risk Groups (INRG): a preliminary report. *Eur J Cancer* 33:2113–2116
31. Fukuda M, Miyajima Y, Miyashita Y et al (2001) Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. *J Pediatr Hematol Oncol* 23:10–13
32. Hansford LM, McKee AE, Zhang L et al (2007) Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. *Cancer Res* 67:11234–11243
33. Monclair T, Brodeur GM, Ambros PF et al (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. *J Clin Oncol* 27:298–303
34. McGregor LM, Rao BN, Davidoff AM et al (2005) The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease. *Cancer* 104:2837–2846
35. Kuroda T, Saeki M, Honna T, Masaki H, Tsunematsu Y (2003) Clinical significance of intensive surgery with intraoperative radiation for advanced neuroblastoma; does it really make sense? *J Pediatr Surg* 38:1735–1738
36. Shorter NA, Davidoff AM, Evance AE et al (1995) The role of surgery in the management of stage IV neuroblastoma: a single institution study. *Med Pediatr Oncol* 24:287–291
37. La Quaglia MP, Kushner BH, Heller G et al (1994) Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. *J Pediatr Surg* 29:1162–1165
38. Hashii Y, Kusafuka T, Ohta H et al (2008) A case series of children with high-risk metastatic neuroblastoma treated with a novel treatment strategy consisting of postponed primary surgery until the end of systemic chemotherapy including high-dose chemotherapy. *Pediatr Hematol Oncol* 25:439–450
39. Canete A, Jovani C, Lopez A et al (1998) Surgical treatment for neuroblastoma: complications during 15 years' experience. *J Pediatr Surg* 33:1526–1530
40. Kaneko M, Ohkawa H, Iwanaka M (1997) Is extensive surgery required for treatment of advanced neuroblastoma? *J Pediatr Surg* 32:1616–1619
41. Kuroda T, Saeki M, Honna T et al (2006) Late complications after surgery in Patients with neuroblastoma. *J Pediatr Surg* 41:2037–2040

# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Factors Affecting Health Care Utilization for Children in Japan**

Yasushi Ishida, Sachiko Ohde, Osamu Takahashi, Gautam A. Deshpande, Takuro Shimbo, Shigeaki Hinohara and Tsuguya Fukui

*Pediatrics* 2012;129:e113; originally published online December 26, 2011;  
DOI: 10.1542/peds.2011-1321

The online version of this article, along with updated information and services, is located on the World Wide Web at:  
<http://pediatrics.aappublications.org/content/129/1/e113.full.html>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2012 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™





# Factors Affecting Health Care Utilization for Children in Japan

**AUTHORS:** Yasushi Ishida, MD, PhD,<sup>a,b</sup> Sachiko Ohde, EdM,<sup>b</sup> Osamu Takahashi, MD, MPH,<sup>b</sup> Gautam A. Deshpande, MD,<sup>b</sup> Takuro Shimbo, MD,<sup>c</sup> Shigeaki Hinohara, MD, PhD,<sup>b</sup> and Tsuguya Fukui, MD, PhD, MPH<sup>b</sup>

<sup>a</sup>Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan; <sup>b</sup>Center for Clinical Epidemiology, St. Luke's Life Science Institute, Tokyo, Japan; and <sup>c</sup>Department of Clinical Research and Informatics, National Center for Global Health and Medicine, Tokyo, Japan

## KEY WORDS

ecology, medical care, physician visit, primary care, health diary

## ABBREVIATION

OR—odds ratio

Dr Ishida participated in the conception and design of the study, analysis and interpretation of data, statistical analysis, and drafting the article; Drs Ohde and Takahashi participated in the conception and design of the study, acquisition of data, analysis and interpretation of data; Dr Deshpande participated in the interpretation of data and drafting the article; Drs Shimbo and Hinohara participated in the interpretation of data and critical revision of the article; Dr Fukui participated in the conception and design of the study, analysis and interpretation of data, and critical revision of the article. Final approval was made by all coauthors.

[www.pediatrics.org/cgi/doi/10.1542/peds.2011-1321](http://www.pediatrics.org/cgi/doi/10.1542/peds.2011-1321)

doi:10.1542/peds.2011-1321

Accepted for publication Oct 11, 2011

Address correspondence to Yasushi Ishida, MD, PhD, Department of Pediatrics, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku, Tokyo 104-0044, Japan. E-mail: yaishida@luke.or.jp

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2012 by the American Academy of Pediatrics

**FINANCIAL DISCLOSURE:** *The authors have indicated they have no financial relationships relevant to this article to disclose.*



**WHAT'S KNOWN ON THIS SUBJECT:** In the United States, the ecology of children's medical care is similar to that of adults. Health care utilization for children varies significantly by age, race, ethnicity, income, and health insurance status.



**WHAT THIS STUDY ADDS:** Compared with data from the United States, children in Japan more frequently visit both community physicians and hospital-based outpatient clinics. Pediatric health care utilization is influenced significantly by age but not affected by income or residence location in Japan.

## Abstract

**BACKGROUND AND OBJECTIVE:** Studies on the ecology of medical care for children have been reported only from the United States. Our objective was to describe proportions of children receiving care in 6 types of health care utilization seeking behaviors in Japan on a monthly basis and to identify care characteristics.

**METHODS:** A population-weighted random sample from a nationally representative panel of households was used to estimate the number of health-related symptoms, over-the-counter medicine doses, and health care utilizations per 1000 Japanese children per month. Variations in terms of age, gender, socioeconomic status, and residence location were also examined.

**RESULTS:** Based on 1286 households (3477 persons including 1024 children) surveyed, on average per 1000 children, 872 had at least 1 symptom, 335 visited a physician's office, 82 a hospital-based outpatient clinic, 21 a hospital emergency department, and 2 a university-based outpatient clinic. Two were hospitalized, and 4 received professional health care in their home. Children had 2 times more physician visits and 3 times more emergency visits than adults in Japan, and Japanese children had 2.5 times more physician visits and 11 times more hospital-based outpatient clinic visits than US children. Pediatric health care utilization is influenced significantly by age but not affected by income or residence location in Japan.

**CONCLUSIONS:** Compared with the data from the United States, more children in Japan visit community physicians and hospital-based outpatient clinics. Results of this study would be useful for further delineation of health care utilization of children in the context of a health care system unique to Japan. *Pediatrics* 2012;129:e113–e119

White et al<sup>1</sup> reported the first study on the ecology of medical care based on the population of the United States and the United Kingdom ~50 years ago. They showed that the main bulk of health service utilization occurred at physician visits (250 out of 1000 per month) with hospitalization comprising only 9 incidences out of 1000. Fukui et al<sup>2</sup> previously revealed that, compared with data in the United States, people in Japan visited community physicians and hospital-based outpatient clinics more frequently. This ecology model has been replicated over several decades,<sup>3–6</sup> including from our group,<sup>2,7,8</sup> with findings that were consistent with those of White et al.<sup>1</sup> This model has subsequently been widely used by both policy makers and educators.<sup>9,10</sup>

Unlike the medical system in the United States, Japan has a universal health care system, which allows virtually free health care access to everyone including children. Per recent Organization for Economic Co-operation and Development data,<sup>11</sup> Japan spent considerably less money, compared with the United States, on health care in terms of total health spending per capita (US\$ 2729 vs 7538 in 2008) and percent of gross domestic product (8.1% vs 16.0% in 2008). Thus, it is speculated that health care-seeking behavior and health service utilization in Japan may be substantially different from that in the United States. However, no well-designed studies on patients' health care-seeking behavior for health-related symptoms have been conducted, although there are reports of limited sample size.<sup>7,12</sup>

To date, studies on the ecology of medical care for children have been reported only from the United States.<sup>13,14</sup> No similar investigation has been made for the Japanese population. The medical ecology of Japanese children's health care may be different from not only

that of Japanese adults but also that of children in the United States. Our objective for this study was to assess health care-seeking behavior of children in Japan by using a nationally representative panel of households.

## METHODS

### Study Design

A prospective cohort design was employed.

### Sample

A nationally representative panel belonging to Japan Statistics and Research Co Ltd that comprised 210 000 households was used (Fig 1). Taking into consideration the size of the cities, towns, and villages, a population weighted random sample of 5387 households was chosen and each household was sent an offer letter with a return envelope. Of the total, 1857 agreed to participate. The sample size was readjusted demographically to 1464 households to make it nationally representative.


### Data Collection

Questionnaires and diaries were used for data collection. The questionnaires were scripted to note children's baseline characteristics including family information. The diary was designed to keep a record of any health-related events, symptoms, health care-seeking behavior, and actual use of health services, along with other variables of interest. Parents or other eligible persons were asked to fill out the questionnaires and diaries for children younger than 13 years and those who could not write on their own. The advantage of health diaries includes the ability to keep a record of events continuously and consistently while minimizing recall bias.

### Definitions of Variables

1. Age: 4 age groups were identified: <2 years, 2 to 5 years, 6 to 12 years, and 13 to 17 years.

2. Gender
3. Education: 3 categories were defined by the highest degree attained by the head of the household in which a child resided: high school or lower, college/vocational school, and university/graduate school.
4. Economic status: family annual income was divided into 3 categories: <5 million Japanese yen, 5 million to 7 million Japanese yen, and >7 million Japanese yen.
5. Residence location: a large city was defined as a city with a population >1 million, a medium-sized city was identified as 100 000 to 1 million, and a small city/town as <100 000 inhabitants. Residents living outside a city or town were defined as rural.
6. Number of children: the number of children in a family was divided into 3 groups: 1 child, 2 children, and ≥3 children.
7. Single-parent households were defined as family units in which a child's mother or father served as the sole caretaker; responses were classified as "yes" or "no."



**FIGURE 1**

Sampling process of this study. Of 1857 households agreeing to participate, the sample size was readjusted to 1464 households to make it nationally representative. Among 3658 persons in 1359 households who returned the diary, we analyzed those of 1024 children and adolescents aged 0 and 17 years.

8. Family living together with grandparents; responses were classified as “yes” or “no”.

### Ethical Considerations

After obtaining informed consent by post, health diaries (divided into 2 parts, each of 2 weeks duration), questionnaires for recording baseline data, and gift vouchers of 3000 Japanese yen (~30 US\$) per person were sent to each member of the 1464 enrolled households in September 2003. The diaries were recorded from October 1, 2003, to October 31, 2003.

A manual accompanied the health diaries to facilitate recording the required information. The diary was in the form of a softbound letter-sized book. Participants were asked to return the first part of the diary after 15 days of entries, whereas the second part was returned after completion of the study period. A weekly phone call to each enrolled family was made as a reminder. Ethical approval was obtained from the research ethics committee of Kyoto University Graduate School of Medicine, Japan.

### Statistical Analysis

Descriptive analyses, along with confidence intervals, were performed to estimate the number of different health care-seeking behaviors per 1000 persons per month. We performed  $\chi^2$  tests or a Fisher's exact test (for any cells with expected counts  $<5$ ) within categorical predictors. Dichotomous analyses indicated strong associations between each predictor variable and participation by children in 1 or more health care settings. Too few children used home care services and university hospitals to produce reliable estimates. Therefore, 4 separate logistic regression analyses were performed to derive adjusted odds ratios (ORs) of the independent association of each predictor variable. All data were analyzed

by SPSS statistical software, version 19.0 (IBM Japan Ltd, Tokyo, Japan).

### RESULTS


Of 1000 children aged 0 to 17 years, on average each month, 872 had at least 1 symptom, 167 visited a physician in the community clinic office setting, 82 visited a hospital-based outpatient clinic, 20 received care in an emergency department, 4 received professional health services in their home, and 2 spent time as an inpatient in a hospital (Fig 2).

Table 1 shows the estimated proportion of children reporting clinical symptoms during a typical month. Most symptoms were significantly dependent on the age of the child. Frequency of symptoms associated with upper respiratory infections (sneezing, cough, fever) or gastrointestinal symptoms (diarrhea and vomiting) was closely correlated with younger age. In contrast, frequency of symptoms associated with pain (sore throat, abdominal pain, headache, leg or toe pain, knee pain, and lumbago) was closely correlated with older age. Children in the older age group (13–17 years) showed similar patterns compared with the

adult group; 8 out of the 10 most frequent symptoms were shared between the 2 groups, with the exception of stiff neck and knee pain, which were more common in adults.

Table 2 compares the ecology of medical care for Japanese children in this study with that of adults in Japan<sup>2</sup> and children in the United States.<sup>13</sup> Nearly the same proportion of Japanese children and adults reported at least 1 symptom (OR = 1.14).<sup>2</sup> The ORs of Japanese children visiting a physician's clinic or outpatient hospital clinic were 2.51 and 11.1, respectively, compared with children in the United States.<sup>13</sup> The ORs associated with Japanese children taking over-the-counter medicine, visiting a physician's community clinic, outpatient hospital clinic, or being admitted to hospital were 0.76, 2.15, 3.04, and 0.25, respectively, compared with Japanese adults.<sup>2</sup>

Table 3 demonstrates the estimate for number of children receiving care in different health care settings, stratified by the child/family sociodemographic characteristics. Univariate analysis using  $\chi^2$  test or Fisher's exact test revealed that children's age, annual income of the family, education level of



**FIGURE 2**

Participation in medical care in a typical month for 1000 children and adolescents aged 0 and 17 years. Boxes visually represent proportional participation categorized by type of medical care; smaller boxes do not indicate inclusive subgroups of larger boxes; 861 participants report some clinical symptoms, 468 take some medicine, 335 visit physician's office, 82 visit a hospital outpatient clinic, 21 visit an emergency clinic, 5 visit a university hospital outpatient clinic, and 2 are hospitalized.

**TABLE 1** Estimated Proportion of Children Experiencing Clinical Symptoms During a Typical Month, *n* (%)

Symptoms	<2 y ( <i>n</i> = 89)	2–5 y ( <i>n</i> = 263)	6–12 y ( <i>n</i> = 468)	13–17 y ( <i>n</i> = 204)	$\chi^2, P$	Total ( <i>n</i> = 1024)	Reference (Japanese adults, <i>n</i> = 2453) <sup>a</sup>
Sneezing	67 (75.3)	168 (63.9)	184 (39.3)	58 (28.4)	<.0001	477 (48.6)	394 (16.1)
Cough	47 (52.8)	161 (61.2)	150 (32.1)	22 (10.8)	<.0001	380 (37.1)	338 (13.8)
Sore throat	7 (7.9)	33 (12.5)	99 (21.2)	59 (28.9)	<.0001	198 (19.3)	441 (18.0)
Fever	33 (37.1)	71 (27.0)	62 (13.2)	24 (11.8)	<.0001	190 (18.6)	166 (6.8)
Abdominal pain	1 (1.1)	30 (11.4)	73 (15.6)	43 (21.1)	<.0001	147 (14.4)	267 (10.9)
Headache	1 (1.1)	9 (3.4)	67 (14.3)	50 (24.5)	<.0001	127 (12.4)	719 (29.3)
Abrasion	7 (7.9)	30 (11.4)	54 (11.5)	5 (2.5)	.001	96 (9.4)	36 (1.5)
Leg or toe pain	1 (1.1)	6 (2.3)	53 (11.3)	25 (12.3)	<.0001	85 (8.3)	191 (7.8)
Common cold	6 (6.7)	20 (7.6)	29 (6.2)	15 (7.4)	.889	70 (6.8)	202 (8.2)
Muscle pain	0	1 (0.4)	25 (5.3)	38 (8.2)	<.0001	64 (6.3)	171 (7.0)
Bruising	9 (10.1)	11 (4.2)	37 (7.9)	6 (2.9)	.016	63 (6.2)	36 (1.5)
Itching	2 (2.2)	24 (9.1)	26 (5.6)	6 (2.9)	.014	58 (5.7)	75 (3.1)
Diarrhea	12 (13.5)	22 (8.4)	18 (3.8)	5 (2.5)	<.0001	57 (5.6)	121 (4.9)
General fatigue	1 (1.1)	6 (2.3)	25 (5.3)	14 (6.9)	.032	46 (4.5)	443 (18.1)
Dermatitis	9 (10.1)	12 (4.6)	17 (3.6)	6 (2.9)	.032	44 (4.3)	40 (1.6)
Nausea	1 (1.1)	9 (3.4)	24 (5.1)	9 (4.4)	.319	43 (4.2)	112 (4.6)
Knee pain	0	4 (1.5)	24 (5.1)	12 (5.9)	.009	40 (3.9)	206 (8.4)
Tooth pain	0	5 (1.9)	21 (4.5)	5 (2.5)	.056	31 (3.0)	112 (4.6)
Vomiting	7 (7.9)	12 (4.6)	11 (2.4)	1 (0.5)	.002	31 (3.0)	14 (0.6)
Hand or finger pain	1 (1.1)	7 (2.7)	19 (4.1)	3 (1.5)	.194	30 (2.9)	86 (3.5)
Dry skin	2 (2.2)	5 (1.9)	15 (3.2)	7 (3.4)	.696	29 (2.8)	28 (1.1)
Lumbago	0	1 (0.4)	13 (2.8)	14 (6.9)	<.0001	28 (2.7)	650 (26.5)

<sup>a</sup> Other common symptoms in adults, *n* (%): stiff neck, 555 (22.6); stomachache, 188 (7.7); shoulder pain, 149 (6.1); and menstrual pain, 130 (6.1).

the head of household, number of children in the family, and single parenthood were significant factors in the health care-seeking behavior of children.

Table 4 shows the results of multivariate analyses. Receipt of care in physicians' community clinic was the most sensitive to various sociodemographic characteristics in the model (age, education level, number of children, and single parenthood), with the exception of annual income and residence

location. Community clinic visits were significantly more likely for younger children compared with children  $\geq 13$  years of age (OR = 7.32,  $P < .001$  for children aged <2 years; OR = 5.66,  $P < .001$  for children aged 2–4 years; OR = 2.41,  $P = .001$  for children aged 6–12 years). Conversely, physicians' clinic visits were significantly less likely for children in families where the head of the household had a university or graduate school level of education

(OR = 0.55,  $P = .008$ ), 3 or more children in the family (OR = 0.55,  $P = .024$ ), or single parenthood (OR = 0.49,  $P = .032$ ; Table 4, including 95% confidence intervals of ORs).

As for over-the-counter medicines, use of these medications increased with older age. Of note, children living with grandparents took less over-the-counter medicines in the multivariate model (Table 4).

Children's age was also the strongest predictor for seeking care in an emergency department (OR = 6.82) and a hospital-based outpatient clinic (OR = 3.31). Families with higher annual income tended to visit community clinics (OR = 1.19) over hospital outpatient clinics (OR = 0.43). Gender and residence location were not independently associated with variation in proportions of children receiving care in any of the health care settings investigated.

## DISCUSSION

This study is the first application of the classic ecology of medical care model to Japanese children. We demonstrate that the same proportion of Japanese children as adults reported at least 1 symptom during the study period<sup>2</sup> and that a substantial proportion of children have an encounter with the health care system in a typical month. Although overall patterns appear generally

**TABLE 2** Ecology of Medical Care for Japanese Children Versus Adults in Japan and children in the United States

	This Study (Children <18 y)	OR of Children in Japan Versus the United States	OR of Japanese Children Versus Adults	Children in the United States (Dovey et al <sup>13</sup> )	Adults in Japan (Fukui et al <sup>2</sup> )	Adults in the United States (Dovey et al <sup>15</sup> )
Having at least 1 symptom	872 (850–892)	NA	1.14 (0.88–1.47)	NA	857 (842–871)	NA
Taking an over-the-counter medicine	468 (442–494)	NA	0.76 (0.64–0.91)	NA	536 (510–562)	NA
Visiting a physician's clinic	335 (306–365)	2.51 (2.03–3.11)	2.15 (1.75–2.64)	167 (161–174)	190 (174–206)	235 (229–241)
Visiting an emergency department	20.5 (12.7–31.2)	1.63 (0.81–3.27)	3.04 (1.29–7.19)	12.8 (11.7–13.9)	6.5 (3.4–11.3)	13.0 (12.2–13.8)
Visiting an outpatient clinic in community hospital	82 (66–101)	11.1 (5.33–23.0)	0.86 (0.63–1.17)	8.2 (7.0–9.4)	94 (81–108)	25.8 (24.0–27.6)
Visiting an outpatient clinic in a university hospital	4.9 (1.6–11.4)	NA	0.71 (0.23–2.26)	NA	6.5 (3.4–11.3)	NA
Requiring hospitalization <sup>a</sup>	2.0 (0.2–7.0)	0.50 (0.09–2.73)	0.25 (0.05–1.17)	3.5 (2.7–4.3)	7.6 (4.4–12.7)	13.3 (9.6–11.0)
Requiring home health care	3.9 (1.1–10.0)	2.00 (0.37–11.0)	1.34 (0.30–5.98)	2.2 (1.4–3.0)	3.3 (1.4–6.4)	17.7 (15.6–19.8)

Values are given as number per 1000 (95% confidence interval) unless otherwise stated. NA, not available.

<sup>a</sup> Excluding hospital stays for birth.

**TABLE 3** Estimates for Number of Children Per 1000 Participating in Health Care in a Typical Month by Sociodemographic Characteristics and Settings (%)

Demographic Characteristic	Taking an Over-The-Counter Medicine	Visiting a Physician's Clinic	Visiting an Emergency Department	Visiting an Outpatient Clinic in a Community Hospital	Visiting an Outpatient Clinic in a University Hospital	Requiring Hospitalization <sup>a</sup>
Age, y	<i>P</i> < .0001	<i>P</i> < .0001	<i>P</i> < .0001	<i>P</i> < .0001	<i>P</i> = .537	—
<2 ( <i>n</i> = 89)	21 (24.7)	52 (59.6)	8 (9.0)	16 (18.0)	1 (1.1)	0
2–5 ( <i>n</i> = 263)	107 (41.8)	115 (44.9)	8 (3.0)	31 (12.2)	1 (0.4)	0
6–12 ( <i>n</i> = 468)	229 (50.0)	134 (29.3)	3 (0.6)	25 (5.6)	3 (0.6)	1 (0.2)
13–17 ( <i>n</i> = 204)	110 (55.4)	34 (17.2)	2 (1.0)	10 (4.9)	0	1 (0.5)
Gender	<i>P</i> = .992	<i>P</i> = .554	<i>P</i> = .068	<i>P</i> = .565	<i>P</i> = .999	<i>P</i> = .999
Boy ( <i>n</i> = 530)	242 (46.8)	178 (34.3)	15 (2.8)	45 (8.7)	3 (0.6)	1 (0.2)
Girl ( <i>n</i> = 494)	226 (46.8)	157 (32.6)	6 (1.2)	37 (7.7)	2 (0.4)	1 (0.2)
Annual income, JPY	<i>P</i> = .597	<i>P</i> = .371	<i>P</i> = .011	<i>P</i> = .020	<i>P</i> = .458	—
<5 million ( <i>n</i> = 342)	164 (46.2)	125 (35.4)	5 (1.5)	37 (10.5)	1 (0.3)	0
5–7 million ( <i>n</i> = 309)	161 (50.2)	104 (32.4)	13 (4.2)	30 (9.4)	3 (1.0)	2 (0.6)
≥7 million ( <i>n</i> = 314)	158 (48.4)	98 (30.3)	3 (1.0)	16 (4.8)	1 (0.3)	0
Education of head of household	<i>P</i> = .040	<i>P</i> = .031	<i>P</i> = .0170	<i>P</i> = .853	<i>P</i> = .801	<i>P</i> = .999
High school or lower ( <i>n</i> = 391)	197 (40.7)	177 (36.6)	10 (2.0)	37 (7.7)	1 (0.3)	1 (0.3)
College/vocational school ( <i>n</i> = 188)	114 (48.9)	74 (31.9)	1 (0.5)	17 (7.4)	1 (0.5)	0
University/graduate school ( <i>n</i> = 228)	141 (50.0)	74 (26.3)	7 (2.6)	25 (8.8)	1 (0.4)	1 (0.4)
Residence location	<i>P</i> = .416	<i>P</i> = .720	<i>P</i> = .464	<i>P</i> = .665	—	—
Large city ( <i>n</i> = 94)	42 (45.7)	33 (36.2)	4 (4.3)	6 (6.4)	1 (1.1)	0
Middle city ( <i>n</i> = 225)	105 (48.0)	72 (32.9)	4 (1.8)	16 (7.1)	0	0
Small town ( <i>n</i> = 450)	194 (44.2)	152 (34.7)	8 (1.8)	41 (9.3)	2 (0.4)	0
Rural area ( <i>n</i> = 255)	126 (50.6)	77 (31.0)	5 (2.0)	20 (7.8)	2 (0.8)	2 (0.8)
Number of children	<i>P</i> = .147	<i>P</i> = .002	<i>P</i> = .248	<i>P</i> = .087	<i>P</i> = .845	<i>P</i> = .213
1 ( <i>n</i> = 165)	70 (41.2)	67 (39.4)	14 (8.5)	3 (1.8)	0	1 (0.6)
2 ( <i>n</i> = 522)	266 (49.4)	188 (34.9)	51 (9.4)	16 (3.1)	3 (0.6)	0
≥3 ( <i>n</i> = 283)	145 (49.8)	72 (24.7)	18 (6.0)	2 (0.7)	2 (0.7)	1 (0.4)
Single parent	<i>P</i> = .002	<i>P</i> = .914	<i>P</i> = .096	<i>P</i> = .841	<i>P</i> = .999	<i>P</i> = .999
Yes ( <i>n</i> = 127)	42 (33.9)	41 (33.1)	0	11 (8.7)	0	0
No ( <i>n</i> = 897)	426 (48.6)	294 (33.6)	21 (2.3)	71 (8.1)	5 (0.6)	2 (0.2)
Living with grandparents	<i>P</i> = .821	<i>P</i> = .795	<i>P</i> = .152	<i>P</i> = .134	<i>P</i> = .590	<i>P</i> = .999
Yes ( <i>n</i> = 182)	92 (48.9)	60 (31.9)	1 (0.5)	10 (5.5)	0	0
No ( <i>n</i> = 788)	390 (48.0)	267 (32.9)	21 (2.5)	72 (8.9)	5 (0.6)	2 (0.3)

JPY, Japanese yen.

<sup>a</sup> Excluding hospital stays for birth.

similar for children and adults,<sup>2</sup> the proportions of each group differed significantly. Despite the same frequency of clinical symptoms,<sup>2</sup> twice as many children visited a community clinic and 3 times as many children visited emergency rooms, whereas the number requiring hospitalization was 4 times that of adults in Japan.<sup>2</sup> Compared with results from the United States,<sup>13</sup> 2.5 times more Japanese children visited a community physician's office or emergency clinic, and 11 times more Japanese children visited hospital-based outpatient clinics.

As expected, age strongly affected the ecology of medical care for children. Among all children, those <2 years of age were less likely to take over-the-counter medicine and most

likely to receive care at least once in a typical month regardless of clinical setting. Children 2 to 5 years of age were more likely than those 13 to 17 years of age to receive care regardless of setting. In contrast, a smaller proportion of children aged 6 to 12 years, compared with those aged 13 to 17 years, received care in emergency departments, whereas the oldest age group comprised the least visits to both outpatient hospital-based and community clinics. These results are consistent with the previous report from the United States.<sup>13</sup> Recently, pediatric professional organizations in the United States and elsewhere have recommended that over-the-counter medications, including cough and cold remedies, should not be given to infants.<sup>15–18</sup> Our data suggest

that Japanese parents restrict use of over-the-counter medications for younger children, especially those younger than 2 years of age. Of note, living with grandparents was associated with significantly reduced over-the-counter medicine use. Several possible interpretations for this association may be considered; grandparents may have a lower threshold taking an ill grandchild to a clinic, or grandparents may be especially adverse to over-the-counter medicine use for children.

Multivariate regression analysis in our study confirmed that children's health care-seeking behavior is affected more substantially by age than by any other socioeconomic characteristics included in our study, a finding also consistent with previous reports from



**TABLE 4** Adjusted ORs (95% Confidence Interval) for Children's Health Care Participation by Sociodemographic Characteristics and Setting

Demographic Characteristic	Taking an Over-the-Counter Medicine	Visiting a Physician's Clinic	Visiting an Emergency Department	Visiting an Outpatient Clinic in Any Hospital
Age, y				
<2	0.18 (0.09–0.36)	7.32 (3.64–14.7)	6.82 (1.22–38.1)	3.31 (1.30–8.46)
2–5	0.42 (0.26–0.69)	5.66 (3.21–9.97)	2.52 (0.47–13.4)	1.56 (0.67–3.66)
6–12	0.72 (0.46–1.11)	2.41 (1.41–4.11)	0.23 (0.02–2.58)	0.82 (0.35–1.93)
13–17	Reference	Reference	Reference	Reference
Gender				
Boy	0.82 (0.60–1.13)	0.90 (0.64–1.26)	0.62 (0.20–1.90)	1.04 (0.60–1.79)
Girl	Reference	Reference	Reference	Reference
Annual income of family, JPY				
<5 million	Reference	Reference	Reference	Reference
5–7 million	0.97 (0.65–1.46)	1.05 (0.69–1.61)	2.40 (0.66–8.74)	0.86 (0.45–1.65)
≥7 million	0.81 (0.53–1.25)	1.19 (0.76–1.87)	1.22 (0.24–6.09)	0.43 (0.19–0.96)
Education of head of household				
High school or lower	Reference	Reference	Reference	Reference
College/vocational School	1.40 (0.91–2.13)	0.75 (0.49–1.17)	0.19 (0.02–1.56)	1.11 (0.53–2.32)
University/graduate school	1.17 (0.77–1.77)	0.55 (0.35–0.86)	0.81 (0.25–2.67)	1.80 (0.88–3.68)
Residence location				
Large city	0.72 (0.40–1.28)	0.78 (0.42–1.43)	1.03 (0.21–5.04)	0.64 (0.22–1.88)
Middle city	0.75 (0.47–1.20)	0.85 (0.51–1.40)	0.28 (0.03–2.55)	0.88 (0.39–2.00)
Small town	0.76 (0.51–1.13)	0.89 (0.58–1.36)	0.61 (0.17–2.21)	1.05 (0.54–2.03)
Rural area	Reference	Reference	Reference	Reference
Number of children				
1	Reference	Reference	Reference	Reference
2	1.26 (0.83–1.91)	0.66 (0.42–1.01)	1.95 (0.50–7.68)	1.03 (0.52–2.03)
≥3	1.42 (0.88–2.30)	0.55 (0.35–0.86)	1.06 (0.16–7.19)	0.68 (0.28–1.60)
Single parent				
Yes	0.85 (0.48–1.53)	0.49 (0.25–0.94)	—	1.78 (0.69–4.59)
No	Reference	Reference	Reference	Reference
Living with grandparents				
Yes	0.63 (0.40–0.98)	1.06 (0.66–1.72)	0.57 (0.07–4.98)	1.31 (0.59–2.92)
No	Reference	Reference	Reference	Reference

JPY, Japanese yen.

the United States.<sup>13,14</sup> Of particular interest is the physicians' office setting where, adjusting for other variables, fewer children received care if they had 2 or more siblings, a single parent, or were living with a head of household with a higher level of educational attainment. No association of medical access with either annual family income or residence location was demonstrated, a fact to which the robust Japanese universal health care system might plausibly contribute.<sup>19–21</sup> It is interesting to consider that the United States might also anticipate a trend toward the findings in this study if recent health reforms, in addition to promotion of the medical home concept, provide wider insurance coverage to help ensure that all children

have equitable access to appropriate health care resources.<sup>13,22,23</sup>

Although Dovey et al<sup>13</sup> were unable to reproduce estimates of clinical symptoms reported in the original study by White et al,<sup>1</sup> our study produced comparable estimated proportions of reported clinical symptoms for children. Population-based literature on children experiencing clinical symptoms is sparse and outdated. Our nationally representative study provides these estimates for children in Japan according to age group. This study revealed that frequency of symptoms associated with upper respiratory infections or gastrointestinal symptoms was closely correlated with younger age and that frequency of pain symptoms was closely correlated with older age.

This study has important strengths. First, this analysis was based on a nationally representative sample that was large enough to produce reasonably precise estimates of the true proportions of children receiving care. This is particularly helpful to generalize our findings to the Japanese pediatric population at large. Second, data were collected from the surveyed sample by using a medical diary, which minimized recall bias. Shaul et al<sup>24</sup> reported that providing both an adult and child survey to an adult could result in lower response rates. However, the response rate in our study (92.8%) was satisfactory. D'Souza-Vazirani et al<sup>25</sup> showed that mothers are a good source of information regarding children's acute health care use. Third, the summary findings are based on a single cohort.

There are, however, some limitations to our study. First, data were collected during a single month (October). Seasonal variations of disease incidence and prevalence, especially in children, could result in estimates different from the current data. October is soon after school begins in the United States and is a time of relatively high numbers of upper respiratory infections and minor illnesses that may result in a significant increase of health care utilization. In contrast, in Japan, the school year begins in April. As such, October represents a typically uneventful and calm month for children in terms of health status. Second, we did not evaluate the appropriateness of particular health care-seeking behaviors because disease outcome data related to individual children's symptoms were not collected.

## CONCLUSIONS

Compared with the data from the United States, more children in Japan visit both community physicians' clinics and hospital-based outpatient clinics. The health care-seeking behavior of

children was influenced significantly by children's age but not affected by income or location of residence in Japan. Results of this study will be

useful for further delineation of health care-seeking behavior of children in the context of a health care system unique to Japan.

#### ACKNOWLEDGMENT

This study was supported by a research grant from the St. Luke's Life Science Institute.

#### REFERENCES

- White KL, Williams TF, Greenberg BG. The ecology of medical care. *N Engl J Med.* 1961;265:885–892
- Fukui T, Rahman M, Takahashi O, et al. The ecology of medical care in Japan. *JMAJ.* 2005;48(4):163–167
- Thacker SB, Greene SB, Salber EJ. Hospitalizations in a southern rural community: an application of the 'ecology model'. *Int J Epidemiol.* 1977;6(1):55–63
- Green LA, Fryer GE, Jr, Yawn BP, Lanier D, Dovey SM. The ecology of medical care revisited. *N Engl J Med.* 2001;344(26):2021–2025
- Leung GM, Wong IO, Chan WS, Choi S, Lo SV; Health Care Financing Study Group. The ecology of health care in Hong Kong. *Soc Sci Med.* 2005;61(3):577–590
- Yawn BP, Fryer GE, Phillips RL, Dovey SM, Lanier D, Green LA. Using the ecology model to describe the impact of asthma on patterns of health care. *BMC Pulm Med.* 2005;5:7
- Fukui T. Health diary study of Japanese residents in Greater Boston: variables related to high incidence of health problems. *Cult Med Psychiatry.* 1987;11(4):509–520
- Tokuda Y, Ohde S, Takahashi O, et al. Musculoskeletal pain in Japan: prospective health diary study. *Rheumatol Int.* 2007;28(1):7–14
- White KL. The ecology of medical care: origins and implications for population-based healthcare research. *Health Serv Res.* 1997;32(1):11–21
- Godwin M, Grzybowski SC, Stewart M, et al. Need for an Institute of Primary Care Research within the Canadian Institutes of Health Research. *Can Fam Physician.* 1999;45:1405–1409, 1417–1421
- The Japanese Ministry of Health Law. OECD Health Data 2010. Available at: [www.mhlw.go.jp/bunya/iryohoken/iryohoken11/index.html](http://www.mhlw.go.jp/bunya/iryohoken/iryohoken11/index.html). Published 2011. Accessed March 19, 2011
- Tonai S, Maezawa M, Kamei M, Satoh T, Fukui T. Illness behavior of housewives in a rural area in Japan: a health diary study. *Cult Med Psychiatry.* 1989;13(4):405–417
- Dovey S, Weitzman M, Fryer G, et al. The ecology of medical care for children in the United States. *Pediatrics.* 2003;111(5 pt 1):1024–1029
- Dovey SM, Green LA, Phillips RL, Fryer GE. The ecology of medical care for children in the United States: a new application of an old model reveals inequities that can be corrected. *Am Fam Physician.* 2003;68(12):2310
- Kogan MD, Pappas G, Yu SM, Kotelchuck M. Over-the-counter medication use among US preschool-age children. *JAMA.* 1994;272(13):1025–1030
- Rimsza ME, Newberry S. Unexpected infant deaths associated with use of cough and cold medications. *Pediatrics.* 2008;122(2). Available at: [www.pediatrics.org/cgi/content/full/122/2/e318](http://www.pediatrics.org/cgi/content/full/122/2/e318)
- Centers for Disease Control and Prevention (CDC). Nonfatal, unintentional medication exposures among young children—United States, 2001–2003. *MMWR Morb Mortal Wkly Rep.* 2006;55(1):1–5
- Walsh A, Edwards H, Fraser J. Over-the-counter medication use for childhood fever: a cross-sectional study of Australian parents. *J Paediatr Child Health.* 2007;43(9):601–606
- Feinberg E, Swartz K, Zaslavsky A, Gardner J, Walker DK. Family income and the impact of a children's health insurance program on reported need for health services and unmet health need. *Pediatrics.* 2002;109(2). Available at: [www.pediatrics.org/cgi/content/full/109/2/e29](http://www.pediatrics.org/cgi/content/full/109/2/e29)
- Carter TM, Adams MH, Judd AH, Leeper JD, Wang L, Yu J. Children's health insurance status, access to and utilization of health services, and unmet health needs in a rural Alabama school system. *J Rural Health.* 2003;19(4):511–513
- Simpson L, Owens PL, Zodet MW, et al. Health care for children and youth in the United States: annual report on patterns of coverage, utilization, quality, and expenditures by income. *Ambul Pediatr.* 2005;5(1):6–44
- Strickland BB, Jones JR, Ghandour RM, Kogan MD, Newacheck PW. The medical home: health care access and impact for children and youth in the United States. *Pediatrics.* 2011;127(4):604–611
- Kocher R, Sahni NR. Physicians versus hospitals as leaders of accountable care organizations. *N Engl J Med.* 2010;363(27):2579–2582
- Shaul JA, Fowler FJ, Jr, Zaslavsky AM, Homer CJ, Gallagher PM, Cleary PD. The impact of having parents report about both their own and their children's experiences with health insurance plans. *Med Care.* 1999;37(3 Suppl):MS59–MS68
- D'Souza-Vazirani D, Minkovitz CS, Strobino DM. Validity of maternal report of acute health care use for children younger than 3 years. *Arch Pediatr Adolesc Med.* 2005;159(2):167–172